Cambridge, MA based ARIAD Pharmaceuticals, Inc. (ARIA – Analyst Report) is a biopharmaceutical company focused on the discovery, development and commercialization of breakthrough treatments for cancer. ARIAD’s only approved product is Iclusig (ponatinib). Iclusig, a tyrosine kinase inhibitor (TKI), is approved both in the U.S. and EU for the treatment of adults suffering from T315I-positive chronic myeloid leukemia (chronic, accelerated or blast phase) or Philadelphia chromosome positive acute lymphoblastic leukemia or for whom no other TKI therapy is approved.
Top Entertainment
Search
New Posts
Lampreys have ‘fight or flight’ cells, challenging ideas about nervous system evolution
NASA’s budget woes put ambitious space research at risk
A hidden danger lurks beneath Yellowstone
Why fuzzy definitions are a problem in the social sciences
Louis Pasteur’s devotion to truth transformed what we know about health and disease
Leave A Comment